Novo Nordisk Raises 2026 Revenue Target on Strong Wegovy Sales

Novo Nordisk has revised its 2026 revenue forecast upward, driven by strong sales of its popular obesity drug Wegovy. The Danish pharmaceutical company improved its growth expectations, particularly due to rising demand in the U.S. market. The company noted that increased sales of Wegovy, along with other products such as Ozempic used in diabetes treatment, have positively impacted its overall revenue projection. Novo Nordisk plans to exceed its previously announced medium-term targets for 2026. Analysts indicate that Wegovy's growing market share and the strategy of expanding into new markets support the company's growth momentum. However, risks such as increasing competition and pricing pressures are also being considered. Novo Nordisk's updated forecasts have been well received by investors and are expected to have a supportive effect on the company's stock performance. Wegovy's leading position in obesity treatment strengthens the company's long-term growth potential. This is not investment advice.